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Serum hypoadiponectinemia and hyperrestinemia independently links 
insulin resistance to type 2 diabetes (T2DM) and metabolic syndrome (MS). Thus, 
the aim of this study was propose a novel adiponectin-resistin (AR) index by 
unifying the effect of adiponectin and resistin. Then, a novel insulin resistance 
(IRAR) index was proposed by taking into account the AR index. Serum 
adiponectin and resistin levels as well as other insulin resistance, T2DM and MS 
risk factors were tested. Experimental results showed the AR index was more 
stronger correlated with insulin resistance risk factors and had stronger 
association  (df=5; F=51.154; P<0.001) with T2DM and MS susceptibility rather 
than the serum adiponectin (df=5; F=15.680; P<0.001) and resistin (df=5; 
F=40.648; P<0.001) levels alone. Therefore, the AR index looks very strongly links 
insulin resistance to T2DM and MS. Meanwhile, the IRAR index (df=5; F=78.396; 
P<0.001) is a potent useful index of insulin sensitivity in subjects with T2DM and 
MS. 
The metabolic syndrome (MS) drives the twin global epidemics of type 2 diabetes 
mellitus (T2DM) and cardiovascular disease (CVD)1,2,3. T2DM itself is accompanied by 
increased risk for CVD which is conferred by the concomitant risk factors of the MS4,5. 
Serum hypoadiponectinemia and hyperrestinemia independently are associated with 
insulin resistance in several prospective epidemiological studies across a variety of 
population groups6,7,8,9. Since, insulin resistance is a prerequisite root factor for 
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developing T2DM10. It is also the most unifying parameter to characterize the 
pathophysiology of the MS1. Thus, the investigation of the interaction effect of 
adiponectin and resistin in aetiological linking insulin resistance with T2DM and MS is 
looking forward. In addition, the modification of the existing insulin resistance indexes 
by taking into account the interaction effect of adiponectin and resistin merit a potential 
investigation. It hopefully to identify those with undiagnosed T2DM and MS due to 
insulin resistance in order to provide early treatment and prevent or delay the onset of 
long-term complications such as cardiovascular risk.  
 
         Adiponectin (also known as Acrp30, AdipoQ, GBP28, and ApM1) is a 
polypeptide hormone with molecular weight 30kDa (244 amino acids) which modulates 
a number of metabolic processes, including regulates energy homeostasis as well as 
glucose and lipid metabolism11,12. It is also a potent insulin sensitizer in muscle and 
liver12. It is exclusively secreted from adipose tissue into the bloodstream and is very 
abundant in plasma relative to many hormones which representing 0.01% of blood 
circulating proteins13,14. The hormone plays a principal role in the suppression of the 
metabolic derangements that may result in insulin resistance, type 2 diabetes, metabolic 
syndrome and cardiovascular diseases7,10,11,12,13,15.  
       Resistin is also known as "serine/cysteine-rich adipocyte-Specific Secretory 
Factor" (ADSF and FIZZ3)16. It is a putative adipocyte-derived signalling polypeptide 
hormone with molecular weight 12.5kDa and the length is 108 amino acids in human16. 
It acts as a pathogenic factor contributing to insulin resistance by antagonizes insulin 
action, thereby increasing gluconeogenesis and impaired hepatic glucose uptake17,18,19. 
In contrast with adiponectin, resistin has low circulating levels16. However, the blood 
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circulating levels of resistin had been shown up-regulated in subjects with insulin 
resistance, type 2 diabetes, metabolic syndrome and cardiovascular diseases8,9,20,21,22,23. 
                 The novel adiponectin-resistin (AR) index. Experimental results showed  
fasting serum adiponectin (A0) and resistin (R0) levels were strongly correlated with 
insulin resistance indexes and risk factors (Tables 1-3). Besides, serum 
hypoadiponectinemia and hyperresistinemia were significantly associated with T2DM 
and MS susceptibility (Fig. 1-2). Therefore,                                                                                 
                                                                           (1) 
                                        (2) 
Since, fasting serum adiponectin (A0) and resistin (R0) levels were significantly negative 
correlated. Thus, (1) and (2) values are unifying by a multiplication as following 
                                                                              (3)    
Then (3) is logarithmically transformed for normalization,  
                                 (4) 
Lastly, a numerical constant 1 added to the (4) to get a positive integer of the AR index  
                                          (5) 
 
Note: R0 = fasting serum resistin levels in ng/mL;  
          A0 = fasting serum adiponectin levels in µg/mL. 
 
 
 
 
 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
10
.4
19
1.
1 
: P
os
te
d 
30
 J
an
 2
01
0
4 
                    The novel adiponectin-resistin (AR) index showed stronger association 
(df=5; F=51.154; P<0.001) with type 2 diabetes (T2DM) and metabolic syndrome (MS) 
susceptibility rather than the serum adiponectin (df=5; F=15.680; P<0.001) and resistin 
(df=5; F=40.648; P<0.001) levels alone (Fig. 1-3). The value of the AR index was the 
lowest for the control subjects followed by the subjects with MS and T2DM. However, 
the value of the AR index reached the peak when T2DM concurrently with MS. In 
addition, the AR index showed stronger correlation with insulin resistance (IR) indexes 
and risk factors particularly the serum insulin, plasma glucose and whole blood HbA1C 
levels rather than the serum adiponectin and resistin levels alone (Tables 1-3). This 
indicated that the AR index very strongly links insulin resistance to T2DM and  MS 
rather than the serum adiponectin and resistin levels alone. 
The most plausible explanation for the interaction effect of adiponectin and 
resistin in linking insulin resistance with type 2 diabetes and metabolic syndrome is the 
overall multimeric assembly of the resistin is similar to that of adiponectin24. The 
comparable domain architecture of these two adipocyte-specific hormones, despite 
diametrically opposed physiological effects, suggest a common regulatory mechanisms 
for the glucose and lipid homeostasis as well as insulin signalling pathway24.  
Serum hypoadiponectinemia and hyperresistinemia probably coupling to 
mediate the dephosphorylation and deactivation of adenosine 5’-monophosphate-
activated protein kinase (AMPK) both in muscle and liver with up-regulated gene 
expression of the gluconeogenic enzymes11,25,26. This resulting impaired in muscle free 
fatty acids oxidation and hepatic glucose uptake, dephosphorylation of coenzyme A 
carboxylase (ACC), increased of gluconeogenesis and glycogenolysis in the liver which 
eventually lead to free fatty acids and glucose levels in vivo inclined7,11,24.  
Furthermore, the transcription of peroxisome proliferator-activated receptor α 
(PPARα) might further down regulated by coupling the serum hypoadiponectinemia and 
hyperresistinemia27,28.  This lead to decrease the levels of molecules involved in free 
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fatty acid transport and energy dissipation which eventually decreased the free fatty 
acids oxidation11,27,28. Up-regulated of resistin followed by down-regulated of PPARγ 
had been showed to inhibit adipocyte differentiation which lead to the reduction of the 
serum adiponectin levels dramatically29. Therefore, the interaction effect of adiponectin 
and resistin showed greater impact in the regulation of glucose and lipid homoeostasis 
rather than adiponectin and resistin alone. A simple schematic of the possible unifying 
mechanism of adiponectin and resistin in linking insulin resistance with type 2 diabetes 
and metabolic syndrome was proposed as shown in the Supplementary Figure S1. 
However, the complete mechanisms behind the interaction effect of the adiponectin and 
resistin on modulating steps in the regulation of energy, glucose and lipid metabolisms 
merit further investigation. 
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   The novel insulin resistance (IRAR) index. Experimental results showed the 
QUICKI index had the most stongest correlation with the adiponectin-resistin (AR) 
index among the existing insulin resistance indexes (Table 3). Therefore, the QUICKI 
index was chosen for a novel insulin resistance index formulation by taking into account 
the AR index.                 
                                                             (6) 
                                                            (5) 
Since, the values of QUICKI and AR indexes were significantly negative correlated 
(Table 3). Therefore, (5) and (6) are unifying by a multiplicative inverse as following 
       
                           
                                                                  (7) 
Lastly, (7) is simplify to become a finalized IRAR index as following  
             (8) 
Note: I0   = fasting serum insulin levels in µU/mL;  
         G0 = fasting serum glucose levels in mg/dL;  
         R0 = fasting serum resistin levels in ng/mL;  
         A0 = fasting serum adiponectin levels in µg/mL. 
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                   The novel IRAR index showed higher sensitivity of the insulin resistance 
(IR) assessment in subjects with type 2 diabetes (T2DM) and metabolic syndrome (MS) 
compared to the other existing IR indexes (Table 4). Besides, the subjects with T2DM 
and MS showed higher values of the IRAR index compared to the control subjects (Fig. 
4). This indicated that the insulin resistance is predisposing to T2DM and MS 
susceptibility.  In addition, the severity of the insulin resistance using the IRAR index 
reached the peak when T2DM concurrently with MS (Fig. 4). Therefore, this indicated 
that the insulin resistance is play a principle role in predisposing T2DM to MS which 
trigger the developing of the diabetic complications4,5. 
      These might be explained by the interaction of adiponectin and resistin on 
modulating steps in the insulin-signalling pathway and inducing insulin 
resistance6,9,11,12,22. Serum hypoadiponectinemia and hyperrestinemia antagonizes 
insulin signalling via inhibition of the insulin-induced phosphorylation of Akt 
independent of AMPK pathway, thereby increasing gluconeogenesis and hepatic 
glucose output9,11,18,26,30. The recent study showed it occurred by stimulated expression 
of glucose-6-phosphate (G6Pase), phosphoenolphyruvate carboxykinase (PEPCK), and 
suppressor of cytokine signalling 3 (SOC-3), repressed the expressions of insulin 
receptor substrate 2 (IRS-2) and glucose transporter 2 (GLUT2)9,31. Therefore, the 
coupling of serum hypoadiponectinemia and hyperresistinemia showed stronger 
induction of insulin resistance rather than  serum hypoadiponectinemia and 
hyperresistinemia alone. 
However, these study just a preliminary evaluation for the sensitivity and 
specificity of the novel insulin resistance (IRAR) index. For the validation purposes, the 
euglycemic hyperinsulinemic clamp technique should be used instead as a gold standard 
index of insulin resistance to evaluate the sensitivity and specificity of the IRAR index in 
the assessment of insulin resistance. Therefore, the potential of the novel IRAR index as 
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an alternatif useful index for insulin resistance assessment in general population merit 
further investigation. 
 As a conclusion, the novel adiponectin-resistin (AR) index showed stronger 
association in linking insulin resistance with type 2 diabetes (T2DM) and metabolic 
syndrome (MS) rather than the serum adiponectin and resistin levels alone. Meanwhile, 
the novel insulin resistance (IRAR) index is a potent useful index of insulin sensitivity in 
subjects with T2DM and MS. 
 
Methods Summary 
 
             The subjects classify into three main groups included controls, type 2 diabetes mellitus 
(T2DM) and metabolic syndrome (MS). T2DM and MS subjects defined according to 
World Health Organization (WHO) 1999 diagnostic criteria and International Diabetes 
Federation (IDF) 2005 diagnostic criteria respectively. Serum adiponectin and resistin 
levels were determined using the ELISA assays. The other insulin resistance (IR) risk 
factors such as the serum fasting insulin, total cholesterol, LDL cholesterol, HDL 
cholesterol, triglycerides, plasma glucose and whole blood HbA1C levels were tested. 
The clinical parameters included the blood pressure, body mass index (BMI), waist, and 
waist-to-hip ratio (WHR) also were measured  and calculated. The indirect method of 
insulin resistance assessment performed by using the HOMA, QUICKI, Bennett, 
McAuley (1) and McAuley (2) indexes. Then, followed by the formulation of a novel 
adiponectin-resistin (AR) index by unifying the serum adiponectin and resistin levels. A 
novel insulin resistance (IRAR) index was proposed by integrate the AR index into a 
chosen existing insulin resistance index for the modification. Lastly, statistical analysis 
were performed to evaluate the novel AR and IRAR indexes in linking insulin resistance 
with T2DM and MS respectively. 
 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
10
.4
19
1.
1 
: P
os
te
d 
30
 J
an
 2
01
0
9 
  1. Alberti, K.G., Zimmet, P. & Shaw, J. The metabolic syndrome--a new  
                  worldwide definition. Lancet 366, 1059-1062 (2005). 
              2. Sattar, N., et al. Can metabolic syndrome usefully predict cardiovascular  
                  disease and diabetes? Outcome data from two prospective studies. Lancet  
                  371, 1927-1935 (2008).   
              3. Hwang, Y.C., et al. Metabolic syndrome as a predictor of cardiovascular  
                  diseases and type 2 diabetes in Koreans. Int J Cardiol 134, 313-321 (2009).   
              4. Mazzone, T., Chait, A. & Plutzky, J. Cardiovascular disease risk in type 2  
                  diabetes mellitus: insights from mechanistic studies. Lancet 371, 1800-1809  
                  (2008).  
              5. Sone, H., et al. Components of Metabolic Syndrome and their Combinations  
                  as Predictors of Cardiovascular Disease in Japanese Patients with Type 2  
                  Diabetes. Implications for Improved Definition. Analysis from Japan  
                  Diabetes Complications Study (JDCS). J Atheroscler Thromb (2009). 
   6. Hivert, M.F., et al. Associations of adiponectin, resistin, and tumor necrosis  
                  factor-alpha with insulin resistance. J Clin Endocrinol Metab 93, 3165-3172  
                  (2008).  
   7. Kusminski, C.M. & Scherer, P.E. The road from discovery to clinic:  
                  adiponectin as a biomarker of metabolic status. Nature 86, 592-595 (2009). 
       8. Yang, Y., et al. Resistin and insulin resistance in hepatocytes: resistin   
                   disturbs glycogen metabolism at the protein level. Biomed Pharmacother   
                   63, 366-374 (2009). 
   9. Luo, Z., et al. Resistin induces insulin resistance by both AMPK-dependent  
                  and AMPK-independent mechanisms in HepG2 cells. Endocrine 36, 60-69  
                  (2009). 
  10. Ramachandran, A., Wan Ma, R.C. & Snehalatha, C. Diabetes in Asia.  
                   Lancet (2009). 
   11. Yamauchi, T., et al. Adiponectin stimulates glucose utilization and fatty- 
                     acid oxidation by activating AMP-activated protein kinase. Nat Med 8,  
                     1288-1295 (2002). 
   12. Wang, C., et al. Adiponectin sensitizes insulin signaling by reducing p70  
                     S6 kinase-mediated serine phosphorylation of IRS-1. J Biol Chem 282,  
                     7991-7996 (2007). 
              13. Spranger, J., et al. Adiponectin and protection against type 2 diabetes  
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
10
.4
19
1.
1 
: P
os
te
d 
30
 J
an
 2
01
0
10 
                    mellitus. Lancet 361, 226-228 (2003). 
   14. Rosen, E.D. & Spiegelman, B.M. Review article adipocytes as regulators  
          of energy balance and glucose homeostasis. Nature 444, 847-853 (2006). 
              15. Yun, J.E., et al. Serum adiponectin as a useful marker for metabolic  
                    syndrome in type 2 diabetic patients. Diabetes Metab Res Rev 25, 259- 
                    265 (2009). 
   16. Banerjee, R.R. & Lazar, M.A. Resistin: molecular history and prognosis.  
                    J Mol Med 81, 218-226 (2003). 
   17. Steppan, C.M., et al. The hormone resistin links obesity to diabetes.  
                    Nature 409, 307-312 (2001). 
   18. Banerjee, R.R., et al. Regulation of fasted blood glucose by resistin.  
                    Science 303, 1195-1198 (2004). 
   19. Tokuyama, Y., et al. Serum resistin level is associated with insulin  
                    sensitivity in Japanese patients with type 2 diabetes mellitus.   
                    Metabolism 56, 693-698 (2007). 
   20. McTernan, C.L., et al. Resistin, central obesity, and type 2 diabetes.  
                    Lancet 359, 46-47 (2002). 
   21. Aquilante, C.L., Kosmiski, L.A., Knutsen, S.D. & Zineh, I. Relationship  
                    between plasma resistin concentrations, inflammatory chemokines, and  
                    components of the metabolic syndrome in adults. Metabolism 57, 494- 
                    501 (2008). 
   22. Onuma, H., Osawa, H. & Makino, H. Role of resistin in insulin  
                     resistance. Rinsho Byori 56, 698-704 (2008). 
   23. Chen, B.H., et al. Circulating levels of resistin and risk of type 2  
                    diabetes in men and women: results from two prospective cohorts.  
                    Diabetes Care 32, 329-334 (2009). 
   24. Patel, S.D., Rajala, M.W., Rossetti, L., Scherer, P.E. & Shapiro, L.  
                    Disulfide-dependent multimeric assembly of resistin family hormones.  
                    Science 304, 1154-1158 (2004). 
   25. Kim, S.J., Nian, C. & McIntosh, C.H. Resistin is a key mediator of  
                    glucose-dependent insulinotropic polypeptide (GIP) stimulation of  
                    lipoprotein lipase (LPL) activity in adipocytes. J Biol Chem 282,  
                   34139-34147 (2007). 
   26. Zhou, L., et al. Adiponectin activates AMP-activated protein kinase in  
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
10
.4
19
1.
1 
: P
os
te
d 
30
 J
an
 2
01
0
11 
                       muscle cells via APPL1/LKB1-dependent and phospholipase                   
                       C/Ca2+/Ca2+/calmodulin-dependent protein kinase kinase-dependent  
                       pathways. J Biol Chem 284, 22426-22435 (2009). 
      27. Hartman, H.B., Hu, X., Tyler, K.X., Dalal, C.K. & Lazar, M.A.  
                       Mechanisms regulating adipocyte expression of resistin. J Biol Chem  
                       277, 19754-19761 (2002). 
      28. Gable, D.R., Hurel, S.J. & Humphries, S.E. Adiponectin and its gene  
                       variants as risk factors for insulin resistance, the metabolic syndrome  
                       and cardiovascular disease. Atherosclerosis 188, 231-244 (2006). 
      29. Blagoev, B., et al. Inhibition of adipocyte differentiation by resistin- 
                       like molecule alpha. Biochemical characterization of its oligomeric  
                       nature. J Biol Chem 277, 42011-42016 (2002). 
      30. Li, F.P., et al. Effects of resistin expression on glucose metabolism  
                       and hepatic insulin resistance. Endocrine 35, 243-251 (2009). 
      31. Barnes, K.M. & Miner, J.L. Role of resistin in insulin sensitivity in  
                       rodents and humans. Curr Protein Pept Sci 10, 96-107 (2009). 
 
 
 
              Supplementary Information is linked to the online version of the paper at 
www.nature.com/nature. 
           Acknowledgements This work was supported by University of Malaya postgraduate’s research 
grant (PPP, PS102-2009A), university’s short-term grant (PJP, FS232-2008C), and national’s research 
grant (E-Science, 12-02-03-2044). We are grateful to our lab members for discussions, and Madam 
Farahwahidah for blood samples collection. 
           Author Information The authors declared no conflict of interest. Correspondence and requests for 
materials should be addressed to L.C.H. (lauciahin_4275@yahoo.com). 
 
 
 
 
 
 
 
 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
10
.4
19
1.
1 
: P
os
te
d 
30
 J
an
 2
01
0
12 
Table 1 The correlation of the single insulin resistance risk factors. 
 
IR Risk Factors 
 
 
 
Adiponectin (J)
 (µg/mL) 
 (n = 809) 
Pa (ra)  
Pb (rb)  
Resistin (J)  
(ng/mL) 
(n = 809) 
Pa (ra)  
Pb (rb)  
Adiponectin (J)  
+ Resistin (J)  
 (n = 809) 
Pc (rc)  
Pd (rd) 
AR Index (J) 
(n = 809) 
Pa (ra)  
Pb (rb)  
BMI (kg/m2) (J) 
 
Waist (cm) (J) 
 
WHR (B) 
 
Systolic BP (mmHg) (B) 
 
Diastolic BP (mmHg) (B) 
 
Total cholesterol (mmol/L) (J) 
 
HDL cholesterol (mmol/L) (J) 
 
LDL cholesterol (mmol/L) (J) 
 
Triglyceride (mmol/L) (B) 
 
Glucose (mmol/L) (B) 
 
HbA1C (%) (B) 
 
Insulin  (µU/mL) (B) 
 
Adiponectin (µg/mL) (J) 
 
Resistin (ng/mL) (J) 
 
   0.000***  (-0.160) P 
   0.000***  (-0.146) 
   0.000***  (-0.190) P 
   0.000***  (-0.186) 
   0.000***  (-0.210) S 
   0.000***  (-0.235) 
   0.414        (-0.029) S 
   0.629        (-0.017) 
   0.204        (-0.045) S 
   0.356        (-0.033) 
   0.032*      (+0.076) P 
   0.004**    (+0.101) 
   0.000***  (+0.362) P 
   0.000***  (+0.352) 
   0.112        (+0.056) P 
   0.033*      (+0.075) 
   0.000***  (-0.221) P 
   0.000***  (-0.205) 
   0.000***  (-0.173) S 
   0.000***  (-0.143) 
   0.000***  (-0.226) S 
   0.000***  (-0.211) 
   0.000***  (-0.237) S 
   0.000***  (-0.223) 
NA 
NA 
   0.003**    (-0.105) P 
   0.002**    (-0.110) 
   0.000*** (+0.123) P  
   0.000*** (+0.129) 
   0.000*** (+0.175) P  
   0.000*** (+0.177) 
   0.000*** (+0.212) S 
   0.000*** (+0.187) 
   0.134       (+0.053) S 
   0.104       (+0.057) 
   0.397       (+0.030) S 
   0.580       (+0.019) 
   0.124       (-0.054) P 
   0.163       (-0.049) 
   0.006**   (-0.097) P 
   0.004**   (-0.102) 
   0.260       (-0.040) P 
   0.316       (-0.035)  
   0.459       (+0.026) P 
   0.362       (+0.032) 
   0.000*** (+0.307) S 
   0.000*** (+0.280) 
   0.000*** (+0.328) S 
   0.000*** (+0.311) 
   0.000*** (+0.160) S 
   0.000*** (+0.131) 
   0.003**   (-0.105) P 
   0.002**   (-0.110) 
NA 
NA 
0.000*** (0.192) 
0.000*** (0.195) 
0.000*** (0.246) 
0.000*** (0.256) 
0.000*** (0.278) 
0.000*** (0.300) 
0.142       (0.069) 
0.060       (0.060) 
0.743       (0.027) 
0.310       (0.038) 
0.041*     (0.089) 
0.000*** (0.113) 
0.000*** (0.366) 
0.000*** (0.367) 
0.177       (0.065) 
0.008**   (0.083) 
0.000*** (0.221) 
0.000*** (0.209) 
0.000*** (0.302) 
0.000*** (0.316) 
0.000*** (0.359) 
0.000*** (0.376) 
0.000*** (0.256) 
0.000*** (0.259) 
NA 
NA 
NA 
NA 
  0.000*** (+0.185) P 
  0.000*** (+0.184) 
  0.000*** (+0.245) P 
  0.000*** (+0.245) 
  0.000*** (+0.270) S 
  0.000*** (+0.278) 
  0.562       (+0.020) S 
  0.398       (+0.030) 
  0.054       (+0.068) S 
  0.373       (+0.031) 
  0.013*     (-0.087) P 
  0.005**   (-0.099) 
  0.000*** (-0.276) P 
  0.000*** (-0.274) 
  0.093       (-0.059) P 
  0.054       (-0.068) 
  0.000*** (+0.138) P 
  0.000*** (+0.133) 
  0.000*** (+0.328) S 
  0.000*** (+0.302) 
  0.000*** (+0.372) S 
  0.000**   (+0.359) 
  0.000*** (+0.239) S 
  0.000*** (+0.222) 
NA 
NA 
NA 
NA 
For descriptive purposes, the sign of correlation coefficient (+/-) are presented using untransformed variables. 
For hypothesis testing purposes, the values of correlation coefficient (r) is presented using transformed variables.  
Skewed variables or outliers dealing by using Johnson transformation (J) [1] or Box-Cox Power Transformation (B) [1].  
Proceed with non-parametric test for skewed variables and/or if the outliers keep emerging after the data transformation. 
ra = Pearson Product Moment Correlation Coefficient (P) [2] / Spearman’s Rho Rank Correlation Coefficient (S) [2] 
rb = Partial Correlation Coefficient using 10,000 Stratified Bootstrap Samples with Bias Corrected and Accelerated 95% CI [2] 
       (multiple testing bias corrections with controlling for covariate ages and stratified ethnics, T2DM and MS status)                
rc = Multiple Correlation Coefficient [3]                                                                                                  
rd = Partial Redundancy Correlation Coefficient with permutation 10,000X [4]   
       (controlling for covariate ages, ethnics, T2DM and MS) 
[1] Minitab 15 Program   [2] PASW Statistics 18    [3] statistiXL 1.8 Program   [4] XLSTAT Program                     
Significant levels: P*<0.05, P**<0.01, P***<0.001 
Note: IR = insulin resistance; BMI = body mass index; WHR = waist-to-hip ratio; BP = blood pressure; NA = not applicable            
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Table 2 The correlation of the multiple insulin resistance risk factors. 
 
IR Risk Factors 
Adiponectin (J) 
(µg/mL) 
(n=809) 
Pa (ra) 
Resistin (J) 
(ng/mL) 
(n=809) 
Pa (ra) 
Adiponectin (J) 
+ Resistin (J) 
(n=809) 
Pb (rb) 
AR Index (J) 
(n=809) 
Pa (ra) 
2 Variables Combination : 
BMI (J)   +  HDL (J) 
BMI (J)   +  TG (B) 
BMI (J)   +   Insulin (B) 
Waist (J)   +  HDL (J) 
Waist (J)   +  TG (B) 
Waist (J)   +   Insulin (B) 
SBP (B)   +  DBP (B) 
TC (J)   +  LDL (J) 
HDL (J)   +  LDL (J) 
HDL (J)   +  TG (B) 
HDL (J)   +  Insulin (B) 
TG (B)   +  Insulin (B) 
Glucose (B)   +  HbA1C (B) 
Glucose (B)  +  Insulin (B) 
HbA1C (B)   +  Insulin (B) 
3 Variables Combination: 
BMI (J)   +  HDL (J)   +  TG (B) 
BMI (J)   +  HDL (J)   +   Insulin (B) 
BMI (J)   +  TG (B)   +   Insulin (B) 
Waist (J)   +  HDL (J)   + TG (B) 
Waist (J)   +  HDL (J)   + Insulin (B) 
Waist (J)   +  TG (B)   + Insulin (B) 
HDL (J)   +  LDL(J)   + TG (B) 
HDL(J)  +  LDL (J)   + Insulin (B) 
HDL (J)  +  TG (B)   + Insulin (B) 
Glucose (B)   +  HbA1C (B)   +  Insulin (B)  
4 Variables Combination: 
BMI (J)  + HDL(J)  + TG (B)  + Insulin (B) 
Waist (J)  + HDL(J)  + TG (B)  + Insulin (B) 
HDL(J)  + LDL(J)  + TG (B)  + Insulin (B) 
 
0.000*** (0.374) 
0.000*** (0.253) 
0.000*** (0.242) 
0.000*** (0.381) 
0.000*** (0.271) 
0.000*** (0.249) 
0.720      (0.029) 
0.072      (0.081) 
0.000*** (0.362) 
0.000*** (0.373) 
0.000*** (0.385) 
0.000*** (0.288) 
0.000*** (0.221) 
0.000*** (0.265) 
0.000*** (0.295) 
 
0.000*** (0.383) 
0.000*** (0.387) 
0.000*** (0.292) 
0.000*** (0.389) 
0.000*** (0.390) 
0.000*** (0.298) 
0.000*** (0.374) 
0.000*** (0.385) 
0.000*** (0.391) 
0.000*** (0.295) 
 
0.000*** (0.393) 
0.000*** (0.396) 
0.000*** (0.392) 
 
0.000*** (0.145) 
0.002**  (0.123) 
0.000*** (0.147) 
0.000*** (0.186) 
0.000*** (0.175) 
0.000*** (0.181) 
0.021*     (0.098) 
0.254       (0.058) 
0.015*     (0.102) 
0.020*     (0.098) 
0.000*** (0.141) 
0.002**   (0.126) 
0.000*** (0.315) 
0.000*** (0.288) 
0.000*** (0.313) 
 
0.001**    (0.147) 
0.000***  (0.158) 
0.001**    (0.147) 
0.000***  (0.188) 
0.000***  (0.188) 
0.000***  (0.181) 
0.036*      (0.103) 
0.001**    (0.143) 
0.001**    (0.143) 
0.000***   (0.322) 
 
0.000***  (0.161) 
0.000***  (0.191) 
0.002**    (0.145) 
 
0.000*** (0.384) 
0.000*** (0.260) 
0.000*** (0.270) 
0.000*** (0.396) 
0.000*** (0.290) 
0.000*** (0.288) 
0.065      (0.103) 
0.121      (0.095) 
0.000*** (0.367) 
0.000*** (0.377) 
0.000*** (0.395) 
0.000*** (0.298) 
0.000*** (0.364) 
0.000*** (0.357) 
0.000*** (0.397) 
 
0.000*** (0.390) 
0.000*** (0.399) 
0.000*** (0.305) 
0.000*** (0.401) 
0.000*** (0.406) 
0.000*** (0.317) 
0.000*** (0.378) 
0.000*** (0.395) 
0.000*** (0.400) 
0.000*** (0.400) 
 
0.000*** (0.403) 
0.000*** (0.409) 
0.000*** (0.400) 
 
0.000*** (0.309) 
0.000*** (0.214) 
0.000*** (0.248) 
0.000*** (0.337) 
0.000*** (0.265) 
0.000*** (0.275) 
0.216     (0.062) 
0.020*    (0.098) 
0.000*** (0.278) 
0.000*** (0.279) 
0.000*** (0.316) 
0.000*** (0.244) 
0.000*** (0.365) 
0.000*** (0.358) 
0.000*** (0.395) 
 
0.000*** (0.309) 
0.000*** (0.326) 
0.000*** (0.259) 
0.000*** (0.338) 
0.000*** (0.345) 
0.000*** (0.285) 
0.000*** (0.281) 
0.000*** (0.317) 
0.000*** (0.316) 
0.000*** (0.400) 
 
0.000*** (0.326) 
0.000*** (0.345) 
0.000*** (0.317) 
 
Skewed variables or outliers dealing by using Johnson transformation (J) [1] or Box-Cox Power Transformation (B) [1].  
Factor Analysis with Principle Component Extraction Method [3] used to identify factors combination for multiple correlations.    
 ra = Multiple Correlation Coefficient [2]             rb = Canonical Correlation Coefficient [2]  
[1] Minitab 15 Program    [2] statistiXL 1.8 Program     [3] XLSTAT Program    
Significant levels : P*<0.05, P**<0.01, P***<0.001                          
Note: IR = insulin resistance; BMI = body mass index; WHR = waist-to-hip ratio; BP = blood pressure; NA = not applicable        
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Table 3 The correlation of the insulin resistance indexes. 
IR Indexes Adiponectin (J) 
(n = 809) 
Pa (ra) 
Pb (rb) 
Resistin (J) 
(n = 809) 
Pa (ra) 
Pb (rb) 
Adiponectin (J) + Resistin (J) 
(n = 809) 
Pc (rc) 
Pd (rd) 
AR Index (J) 
(n = 809) 
Pa (ra) 
Pb (rb) 
HOMA Index (B) 
 
 
QUICKI Index (J) 
 
 
Bennett Index (J) 
 
 
McAuley (1) Index (J) 
 
 
McAuley (2) Index (J) 
 
 
0.000*** (-0.258) P
0.000*** (-0.243) 
 
0.000*** (+0.290) P 
0.000*** (+0.275) 
 
0.000*** (+0.276) P 
0.000*** (+0.263) 
 
0.000*** (+0.286) P 
0.000*** (+0.271) 
 
0.000*** (+0.288) P 
0.000*** (+0.272) 
0.000*** (+0.224) P
0.000*** (+0.232) 
 
0.000*** (-0.247) P 
0.000*** (-0.241) 
 
0.000*** (-0.221) P 
0.000*** (-0.229) 
 
0.002**  (-0.109) P 
0.001**  (-0.117) 
 
0.001**   (-0.118) P 
0.000*** (-0.126) 
0.000*** (0.325) 
0.000*** (0.340) 
 
0.000*** (0.389) 
0.000*** (0.364) 
 
0.000*** (0.336) 
0.000*** (0.351) 
 
0.000*** (0.297) 
0.000*** (0.298) 
 
0.000*** (0.301) 
0.000*** (0.303) 
0.000*** (+0.319) P 
0.000*** (+0.313) P 
 
0.000*** (-0.364) P 
0.000*** (-0.358) 
 
0.000*** (-0.330) P 
0.000*** (-0.329) 
 
0.000*** (-0.242) P 
0.000*** (-0.235) 
 
0.000*** (-0.250) P 
0.000*** (-0.244) 
For descriptive purposes, the sign of correlation coefficient (+/-) are presented using untransformed variables.  
For hypothesis testing purposes, the values of correlation coefficient (r) is presented using transformed variables.  
Skewed variables or outliers dealing by using Johnson transformation (J) [1] or Box-Cox Power Transformation (B) [1].  
ra = Pearson Product Moment Correlation Coefficient (P) / Spearman’s Rho Rank Correlation Coefficient (S) [2]  
rb = Partial Correlation Coefficient using 10,000 Stratified Bootstrap Samples with Bias Corrected and Accelerated 95% CI [2]  
      (multiple testing bias corrections with controlling for covariate ages and stratified ethnics, T2DM and MS status)                
rc = Multiple Correlation Coefficient [3]                                                                                                   
rd = Partial Redundancy Correlation Coefficient with permutation 10,000X [4]  
       (controlling for covariate ages, ethnics, T2DM and MS) 
[1] Minitab 15 Program        [2] PASW Statistics 18         [3] statistiXL 1.8 Program   [4] XLSTAT Program                        
Note: IR = insulin resistance; HOMA = Homeostasis Model Assessments index; 
         QUICKI = Quantitative Insulin Sensitivity Check index                   Significant levels: P*<0.05, P**<0.01, P***<0.001 
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Table 4 The sensitivity and specificity of the insulin resistance indexes. 
 
IR Indexes 
T2DM  
Sensitivity (%) 
95% CI (%) 
MS  
Sensitivity (%) 
95% CI (%) 
Without MS 
(208 controls) 
(171 cases) 
(n = 379) 
With MS 
(208 controls) 
(256 cases) 
(n = 464) 
Total 
(208 controls) 
(427 cases) 
(n = 635) 
Without 
T2DM 
(208 controls) 
(174 cases) 
(n = 382) 
With T2DM 
(208 controls) 
(256 cases) 
(n = 464) 
Total 
(208 controls) 
(430 cases) 
(n = 638) 
HOMA Index 
(IR ≥ 4.520) 
 
36.30 
(29.40, 43.70) 
 
36.30 
(29.40, 43.70) 
 
40.40 
(33.30, 47.80) 
 
14.60 
(10.10, 20.80) 
 
12.30 
(8.10, 18.10) 
 
47.40 
(40.00, 54.80) 
65.60 
(59.60, 71.20) 
 
65.60 
(59.60, 71.20) 
 
71.90 
(66.10, 77.00) 
 
53.10 
(47.00, 59.10) 
 
57.40 
(51.30, 63.30) 
 
73.80 
(68.10, 78.80) 
53.90 
(49.10, 58.50) 
 
53.90 
(49.10, 58.50) 
 
59.30 
(54.50, 63.80) 
 
37.70 
(33.20, 42.40) 
 
39.30 
(34.80, 44.10) 
 
63.20 
(58.60, 67.70) 
34.50 
(27.80, 41.80) 
 
34.50 
(27.80, 41.80) 
 
33.90 
(27.30, 41.20) 
 
54.00 
(46.60, 61.30) 
 
57.50 
(50.00, 64.60) 
 
42.50 
(35.40, 50.00) 
65.60 
(59.60, 71.20) 
 
65.60 
(59.60, 71.20) 
 
71.90 
(66.10, 77.00) 
 
53.10 
(47.00, 59.10) 
 
57.40 
(51.30, 63.30) 
 
73.80 
(68.10, 78.80) 
53.00 
(48.30, 57.70) 
 
53.00 
(48.30, 57.70) 
 
56.50 
(51.80, 61.10) 
 
53.50 
(48.80, 58.10) 
 
57.40 
(52.70, 62.00) 
 
60.70 
(56.00, 65.20) 
QUICKI Index 
(IR ≤ 0.307) 
 
Bennett Index 
(IR ≤ 0.202) 
 
McAuley (1) Index 
(IR ≤ 5.360) 
 
McAuley (2) Index 
(IR ≤ 5.660) 
 
IRAR Index 
(IR ≥ 4.683) 
 
Data are expressed as values (95% Confident Interval) in % using XLSTAT Program. 
For the purposes of the sensitivity comparison, the specificity for all insulin resistance (IR) indexes was maintained at 90%. 
Test data values threshold (X ≤ IR or IR ≥ X) indicated the positive event of insulin resistance (IR) assessment in subjects.  
Note: T2DM = type 2 diabetes; MS = metabolic syndrome; IR = insulin resistance 
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Figure 1 | The association of the serum adiponectin levels with T2DM and MS 
susceptibility. For descriptive purposes, the mean values with 95% CI are presented 
using untransformed and unadjusted variables. For hypothesis testing purposes, the 
variable was transformed using  Box-Cox Power Transformation [1]. ANCOVA Test [2] 
in General Linear Model was used with adjustment the covariate effect of ages and 
ethnics. Pairwise Comparisons using 1,000 Stratified Bootstrap Samples with Bias 
Corrected and Accelerated (BCa) 95% CI [2] for multiple testing bias corrections with 
adjusted covariate effect of ages and stratified ethnic’s status.   The location of 
statistically significant differences are showed in the legend of the Figure 1 as A > D/E 
and B/C > F. Two-tailed p-value was used for the tests. [1] Minitab 15 Program [2] 
PASW Statistics 18 Program  Note: T2DM = type 2 diabetes; MS = metabolic 
syndrome.            
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Figure 2 | The association of the serum resistin levels with T2DM and MS 
susceptibility. For descriptive purposes, the mean values with 95% CI are presented 
using untransformed and unadjusted variables. For hypothesis testing purposes, the 
variable was transformed using  Johnson Transformation [1]. ANCOVA Test [2] in 
General Linear Model was used with adjustment the covariate effect of ages and 
ethnics. Pairwise Comparisons using 1,000 Stratified Bootstrap Samples with Bias 
Corrected and Accelerated (BCa) 95% CI [2] for multiple testing bias corrections with 
adjusted covariate effect of ages and stratified ethnic’s status. The location of 
statistically significant differences are showed in the legend of the Figure 2 as A< C/E 
and B/D < F. Two-tailed p-value was used for the tests. [1] Minitab 15 Program  [2] 
PASW Statistics 18 Program   Note: T2DM = type 2 diabetes; MS = metabolic 
syndrome.                      
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            Figure 3 | The association of the adiponectin-resistin (AR) index with T2DM 
and MS susceptibility. For descriptive purposes, the mean values with 95% CI 
are presented using unadjusted variables. No transformation of the variables had 
been done since variable is normally distributed, no outlier detected and                             
homogeneity of variances for each group of subject. ANCOVA Test [2] in 
General Linear Model was used with adjustment the covariate effect of ages and 
ethnics. Pairwise Comparisons using 1,000 Stratified Bootstrap Samples with 
Bias Corrected and Accelerated (BCa) 95% CI [2] for multiple testing bias 
corrections with adjusted covariate effect of ages and stratified ethnic’s status.  
The location of statistically significant differences are showed in the legend of 
the Figure 3 as A< D/E and B/C < F. Two-tailed p-value was used for the tests. 
[1] Minitab 15 Program  [2] PASW Statistics 18 Program  Note: T2DM = type 2 
diabetes; MS = metabolic syndrome.        
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            Figure 4 | The assessment of insulin resistance in subjects with T2DM and 
MS by using a novel IRAR index. For descriptive purposes, the mean values 
with 95% CI are presented using unadjusted variables. No transformation of the 
variables had been done since variable is normally distributed, no outlier 
detected and homogeneity of variances for each group of subject. ANCOVA 
Test [2] in General Linear Model was used with adjustment the covariate effect 
of ages and ethnics. Pairwise Comparisons using 1,000 Stratified Bootstrap 
Samples with Bias Corrected and Accelerated (BCa) 95% CI [2] for multiple 
testing bias corrections with adjusted covariate effect of ages and stratified 
ethnic’s status.  The location of statistically significant differences are showed in 
the legend of the Figure 4 as A< B < C < D < E < F. Two-tailed p-value was 
used for the tests. [1] Minitab 15 Program  [2] PASW Statistics 18 Program  
Note: IR = insulin resistance; T2DM = type 2 diabetes; MS = metabolic 
syndrome.            
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                 Methods 
                 Subjects. All subjects were native to Malaysia. The ages for all subjects were 
restricted to 40-70 years old and males in gender for the homogeneity of the subjects 
purposes. The subjects comprised three primary ethnic groups of Malaysian subjects 
which were Malay, Chinese and Indian.  All the subjects were from the University 
Malaya Medical Centre (UMMC). The study design used was randomized case-control 
study. Ethical clearance (612.17) to undertake this study was obtained from the UMMC 
Ethics Committee and informed consent was obtained from each subject. Each subject 
received a detailed questionnaire about the personal and family disease history followed 
by the demographic data measurement.  
  The subjects classify into three main groups which were controls, type 2 
diabetes mellitus (T2DM) and metabolic syndrome (MS). T2DM and MS subjects 
defined according to World Health Organization (WHO) 1999 diagnostic criteria32 and 
International Diabetes Federation (IDF) 2005 diagnostic criteria33 respectively. T2DM 
subjects further divided into subgroups without MS and with MS. Meanwhile, MS 
subjects further divided into subgroups without T2DM and with T2DM. The criteria for 
each group of subjects defined with clearly in the Supplementary Methods. The 
minimum samples size for each group of subjects calculated by using the PS Power and 
Sample Size Calculation Version 3.0.12 Program6. The justification for the samples size 
calculation explained with detail in the Supplementary Methods. 
                  Serum adiponectin and resistin levels measurement. Serum adiponectin 
levels were determined using the AssayMax Human Adiponectin ELISA Kit (AssayPro, 
USA) while serum resistin levels were detected using the AssayMax Human Resistin 
Elisa Kit (AssayPro, USA). For the adiponectin assayed, the intra-assay and inter-assay 
coefficients of variation were 4.1% and 7.2% respectively with a sensitivity of 0.5ng/ml. 
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Meanwhile, the intra-assay and inter-assay coefficients of variation were 4.0% and 7.2% 
respectively with a sensitivity of <100pg/mL for the resistin assayed.  
                  Other insulin resistance risk factors measurement. The other biochemical 
parameters including serum fasting insulin, total cholesterol, LDL cholesterol34, HDL 
cholesterol, triglycerides, plasma glucose and whole blood HbA1C levels were tested. 
The clinical parameters including the blood pressure, body mass index (BMI), waist, 
and waist-to-hip ratio (WHR) also were measured and calculated.  The procedure of the 
measurements for these biochemical and clinical parameters are shown detailed in the 
Supplementary Methods. 
       Insulin resistance assessment. The indirect methods of the insulin 
sensitivity evaluation included the Homeostasis Model Assessments index (HOMA)35, 
Quantitative Insulin Sensitivity Check index (QUICKI)35, Bennett index36, McAuley (1) 
index35 and McAuley (2)36 index were used to assess the insulin resistance for each 
subjects. The mathematical equations for each insulin resistance indexes  with its 
corresponding components’ units are shown in the Supplementary Table S1. 
                  The formulation and evaluation of the novel AR and IRAR indexes. The 
experimental results used to derive a novel adiponectin-resistin index (AR) by unifying 
the effect of serum adiponectin and resistin levels. Then, a novel insulin resistance 
(IRAR) index was proposed by integrate the AR index into a chosen existing insulin 
resistance index for the modification. The sensitivity and specificity of the novel IRAR 
indexes as compared to the other existing insulin resistance indexes were evaluated by 
XLSTAT program (Addinsoft, USA). Lastly, statistical analysis were performed to 
evaluate the novel AR and IRAR indexes in linking insulin resistance with type 2 
diabetes and metabolic syndrome respectively. 
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                   Statistical analysis. Classical statistical analysis included the normality test 
(Anderson-Darling test followed by P-P and Q-Q plots), equality of variance test 
(Barlett’s test or Levene’s test), outliers’ detection (Box plot) and data transformation 
were performed using the Minitab 15 Program (Minitab Inc, USA). The best fitted 
transformation of variables perfomed with Johnson transformation or Box-Cox 
transformation. Meanwhile, the resampling statistical analysis included the analysis of 
covariance (ANCOVA) and Partial Correlation test with bootstrapping method using 
Bias Corrected and Accelerated (BCa) 95% CI were performed using the PASW 
Statistics 18 Program (SPSS Inc, USA). The statistiXL 1.8 Program (Addinsoft, USA) 
was used for the parametric Pearson Product Moment Correlation test, nonparametric 
Spearman’s Rho Rank Correlation test, Multiple Correlation test and Factor Analysis. 
Meanwhile, the XLSTAT Program (Addinsoft, USA) was used for the Canonical 
Correlation and Partial Redundancy Correlation tests. Data are expressed as mean (95% 
confident interval) for parametric test and median (95% confident interval) for 
nonparametric test. All p-values were two-tailed, and p-values below 0.05 were 
considered statistically significant. The details of statistical analysis used with its 
justification are shown in Supplementary Notes. 
 
               32. Definition and diagnosis of diabetes mellitus and intermediate  
                         hyperglycaemia.  1-46 (World Health Organization (WHO), Geneva,  
                         2006). 
                   33. The IDF consensus worldwide definition of the metabolic syndrome.  1- 
                          23 (International Diabetes Federation (IDF), Belgium, 2006). 
        34. Tremblay, A.J., et al. Validation of the Friedewald formula for the  
                         determination of low-density lipoprotein cholesterol compared with  
                         beta-quantification in a large population. Clin Biochem 37, 785-790  
                          (2004). 
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         35. Hettihewa, L.M., Palangasinghe, S., Jayasinghe, S.S., Gunasekara, S.W.  
                          & Weerarathna, T.P. Comparison of insulin resistance by indirect  
                          methods - HOMA, QUICKI and McAuley - with fasting insulin in  
                          patients with type 2 diabetes in Galle, Sri Lanka: a pilot study. Online  
                          Journal of Health and Allied Sciences 5, 1-8 (2006). 
          36. McAuley, K.A., et al. Diagnosing insulin resistance in the general  
                           population. Diabetes Care 24, 460-464 (2001). 
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